益生菌对非酒精性脂肪肝相关细胞的作用

王斌; 蔡敏; 黄玲; 姜子廷; 童敏思; 李力

doi:10.3969/j.issn.1006-0111.2018.05.006

益生菌对非酒精性脂肪肝相关细胞的作用

doi: 10.3969/j.issn.1006-0111.2018.05.006

同济大学附属杨浦医院消化科, 上海 200090

Role of probiotics on nonalcoholic fatty liver disease related cells

Department of Gastroenterology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China

摘要: 目的探讨益生菌对非酒精性脂肪肝相关的肠上皮细胞、肝Kupper细胞和肝实质细胞的作用及其作用机制。方法将人肠上皮细胞Caco-2、大鼠肝Kupper细胞和小鼠肝实质细胞AML12分别分成空白对照组、脂多糖（LPS）组、嗜酸乳杆菌组、LPS+嗜酸乳杆菌组、粪肠球菌组、LPS+粪肠球菌组、双歧杆菌组、LPS+双歧杆菌组，孵育培养6 h。分别检测人肠上皮细胞Caco-2紧密连接相关因子表达情况及细胞通透性、大鼠肝Kupper细胞功能表型相关因子和IκB及p-IκB变化水平、小鼠肝实质细胞AML12脂代谢基因水平和脂类吸收情况。结果益生菌可显著抑制由LPS刺激引起的人肠上皮细胞Caco-2紧密连接相关因子Occludin、Claudin-1、JAM、ZO-1表达的下降和细胞通透性的增加；明显抑制LPS刺激引起的大鼠肝Kupper细胞表达TNF-α、IFN-γ和IL-6的增加，同时抑制IL-4、IL-10、IL-13的降低和p-IκB蛋白表达的增加；显著抑制由LPS刺激引起的小鼠肝实质细胞AML12脂代谢基因ACACA、SREBF1、FAS、FABP3、FABP4、DGAT1的上调和脂类吸收的增加。结论益生菌可以通过促进肠上皮细胞紧密连接相关因子的表达，降低细胞通透性，抑制肝Kupper细胞NF-κB通路活性，降低促炎性细胞因子、增加抑炎性细胞因子表达水平，抑制肝实质细胞脂代谢基因表达和脂类吸收等多种途径，保护非酒精性脂肪肝。
- 非酒精性脂肪肝 /
- 益生菌 /
- Caco-2细胞 /
- 细胞通透性 /
- Kupffer细胞 /
- p-IκB /
- AML12细胞 /
- 脂类吸收
Abstract: Objective To explore the effects and mechanisms of probiotics on nonalcoholic fatty liver disease related intestinal epithelial cells, Kupffer cells and liver parenchymal cells. Methods Human intestinal epithelial cells Caco-2, rat Kupffer cells and mouse liver parenchymal cell AML12 were divided into eight groups respectively:the control group, LPS group, Lactobacillus acidophilus group, LPS+Lactobacillus acidophilus group, Enterococcus faecalis group, LPS+Enterococcus faecalis group, Bifidobacterium group and LPS+Bifidobacterium group. All cells were incubated for 6 h and collected to detect the expression of tight junction related factors and cell permeability of human intestinal epithelial cells Caco-2, the levels of functional factors, IκB and p-IκB of rat Kupffer cells, the expression of lipid metabolism genes and lipid absorption of hepatocytes AML12. Results Probiotics significantly inhibited the expression of Occludin, Claudin-1, JAM, ZO-1 and cell permeability induced by LPS in human intestinal epithelial cells Caco-2. Probiotics decreased the levels of TNF-α, IFN-γ, IL-6 and increased the levels of IL-4, IL-10, IL-13 caused by LPS in rat Kupffer cells. The protein level of p-IκB was also inhibited by probiotics. In addition, probiotics significantly inhibited the upregulation of ACACA, SREBF1, FAS, FABP3, FABP4, DGAT1 and lipid absorption induced by LPS in mouse liver parenchymal cells AML12. Conclusion Probiotics can protect nonalcoholic fatty liver disease through promoting the expression of intestinal epithelial tight junction related factors, reducing epithelial cells permeability, inhibiting the activity of NF-κB pathway to decrease the expression of proinflammatory cytokines and increase the levels of anti-inflammatory cytokines in Kuffer cells, inhibiting lipid metabolism genes expression and lipid absorption of hepatocytes.
- nonalcoholic fatty liver disease /
- probiotics /
- Caco-2 /
- cell permeability /
- Kupffer cell /
- p-IκB /
- AML12 /
- lipid absorption

[1]	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 19(3):163-166.
[2]	KE P, SHAO BZ, XU ZQ, et al. Intestinal autophagy and its pharmacological control in inflammatory bowel disease[J]. Front Immunol, 2016, 7:695.
[3]	XIN D, ZONG-SHUN L, BANG-MAO W, et al. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease[J]. Hepatogastroenterology, 2014, 61(129):136-140.
[4]	BASHIARDES S, SHAPIRO H, ROZIN S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5(9):782-794.
[5]	BAO Y. The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases[J]. Zhonghua Gan Zang Bing Za Zhi, 2017, 25(7):553-556.
[6]	CHEN J, LI J, YIU JHC, et al. TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis[J]. Sci Signal, 2017, 10(491):eaal3336.
[7]	MOUZAKI M, BANDSMA R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease[J]. Curr Drug Targets, 2015, 16(12):1324-1331.
[8]	KELISHADI R, FARAJIAN S, MIRLOHI M. Probiotics as a novel treatment for non-alcoholic fatty liver disease; a systematic review on the current evidences[J]. Hepat Mon, 2013, 13(4):e7233.
[9]	LYU M, WANG YF, FAN GW, et al. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Front Microbiol, 2017, 8:2146.
[10]	LI M, WANG B, SUN X, et al. Upregulation of intestinal barrier function in mice with DSS-induced colitis by a defined bacterial consortium is associated with expansion of IL-17A producing gamma delta T cells[J]. Front Immunol, 2017, 8:824.
[11]	BETRAPALLY NS, GILLEVET PM, BAJAJ JS. Gut microbiome and liver disease[J]. Transl Res, 2017, 179:49-59.
[12]	MU C, YANG Y, ZHU W. Gut microbiota:the brain peacekeeper[J]. Front Microbiol, 2016, 7:345.
[13]	BUDDEN KF, GELLATLY SL, WOOD DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1):55-63.
[14]	ZHU W, GREGORY JC, ORG E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell, 2016, 165(1):111-124.
[15]	SHEN ZH, ZHU CX, QUAN YS, et al. Relationship between intestinal microbiota and ulcerative colitis:mechanisms and clinical application of probiotics and fecal microbiota transplantation[J]. World J Gastroenterol, 2018, 24(1):5-14.
[16]	CAVALCANTI NETO MP, AQUINO JS, ROMAO DA SILVA LF, et al. Gut microbiota and probiotics intervention:a potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?[J]. Pharmacol Res, 2018, 130:152-163.
[17]	WAN MLY, EL-NEZAMI H. Targeting gut microbiota in hepatocellular carcinoma:probiotics as a novel therapy[J]. Hepatobiliary Surg Nutr, 2018, 7(1):11-20.
[18]	钱晓婷,章期生. 双歧杆菌三联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素和炎症因子的影响[J]. 中国微生态学杂志, 2014, 26(4):435-437.
[19]	WANG W, SHI LP, SHI L, et al. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease[J]. Zhonghua Nei Ke Za Zhi, 2018, 57(2):101-106.
[20]	MANZHALⅡ E, VIRCHENKO O, FALALYEYEVA T, et al. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis:a pilot trial[J]. J Dig Dis, 2017, 18(12):698-703.
[21]	DAI X, WANG B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract, 2015, 2015:287348.
[22]	ZHU L, BAKER RD, BAKER SS. Gut microbiome and nonalcoholic fatty liver diseases[J]. Pediatr Res, 2015, 77(1-2):245-251.
[23]	杨群菲,吴建业. 双歧杆菌四联活菌片保护非酒精性脂肪性肝炎患者肠黏膜屏障功能的机制及疗效[J]. 中国微生态学杂志, 2015, 27(6):696-698.
[24]	RITZE Y, BARDOS G, CLAUS A, et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice[J]. PLoS One, 2014, 9(1):e80169.
[25]	MIYAKE Y, YAMAMOTO K. Role of gut microbiota in liver diseases[J]. Hepatol Res, 2013, 43(2):139-146.
[26]	SOHN W, JUN DW, LEE KN, et al. Lactobacillus paracasei induces M2-dominant kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis[J]. Dig Dis Sci, 2015, 60(11):3340-3350.
[27]	ANEST V, HANSON JL, COGSWELL PC, et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression[J]. Nature, 2003, 423(6940):659-663.
[28]	KIM YA, KEOGH JB, CLIFTON PM. Probiotics, prebiotics, synbiotics and insulin sensitivity[J]. Nutr Res Rev, 2018,31(1):35-51.
[29]	SHEN F, ZHENG RD, SUN XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease[J]. HBPD Int, 2017, 16(4):375-381.
[30]	IBRAHIM SH, HIRSOVA P, GORES GJ. Non-alcoholic steatohepatitis pathogenesis:sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut, 2018, 67(5):963-972.
[31]	郑啼婴,李瑜元,聂玉强,等. 肠道菌群对非酒精性脂肪性肝病病变程度的影响[J]. 广州医科大学学报,2016, 1:9-13.
[32]	MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57(2):545-553.
[33]	NABAVI S, RAFRAF M, SOMI MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease[J]. J Dairy Sci, 2014, 97(12):7386-7393.

[1]	李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华. 米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
[2]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[3]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[4]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[5]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[6]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[7]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
[8]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[9]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[10]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[11]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
[12]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[13]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[14]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[15]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[16]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[17]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[18]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[19]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[20]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096

点击查看大图

计量

文章访问数: 3234
HTML全文浏览量: 357
PDF下载量: 435
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

益生菌对非酒精性脂肪肝相关细胞的作用

doi: 10.3969/j.issn.1006-0111.2018.05.006

Role of probiotics on nonalcoholic fatty liver disease related cells

计量

益生菌对非酒精性脂肪肝相关细胞的作用

doi: 10.3969/j.issn.1006-0111.2018.05.006

同济大学附属杨浦医院消化科, 上海 200090

English Abstract

Role of probiotics on nonalcoholic fatty liver disease related cells

Department of Gastroenterology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China

全文HTML

目录

留言板

益生菌对非酒精性脂肪肝相关细胞的作用

doi: 10.3969/j.issn.1006-0111.2018.05.006

Role of probiotics on nonalcoholic fatty liver disease related cells

计量

出版历程

益生菌对非酒精性脂肪肝相关细胞的作用

doi: 10.3969/j.issn.1006-0111.2018.05.006

同济大学附属杨浦医院消化科, 上海 200090

English Abstract

Role of probiotics on nonalcoholic fatty liver disease related cells

Department of Gastroenterology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China

全文HTML

目录